The FDA is being criticized for slowing down approval of COVID-19 vaccines, raising concerns that new rules may delay access to important shots.
Recently, the FDA asked Novavax to run another clinical trial before fully approving its COVID vaccine, which has been available since 2022 under emergency use.
Novavax’s vaccine is different from the popular mRNA vaccines by Pfizer and Moderna and uses traditional technology. The FDA says Novavax is seeking approval for a “new” vaccine targeting a recent COVID variant, so updated data is needed.
Critics argue this is unusual since flu and mRNA vaccines are updated yearly without new trials.
Dr. Paul Offit, a vaccine expert, worries this delay may weaken vaccine efforts. The Department of Health and Human Services says updated trials are necessary for new vaccine versions to ensure safety and effectiveness.
There are also concerns about future approvals, including Pfizer’s vaccine for children under 11. Some political figures and advisers have criticized COVID vaccines, especially for kids, adding to worries about vaccine delays.
Experts stress the importance of keeping vaccine options open, especially for vulnerable groups, as flu and COVID continue to cause many deaths each year.
The debate highlights the challenge of balancing safety with quick access to vaccines during ongoing health threats.
Read more:
- Smartphone App Shows Promise In Boosting Mental Health, Study Finds
- Staffing Cuts Threaten Future Of 9/11 Health Program
- New Mpox Strain Detected In Several European Countries: What You Need To Know
